邦瑞得与密盖息治疗POP的疗效比较

Comparison of Efficacy Between D-Cal and Miacalcic in Treatment of Primary Osteoporosis

目的评价国产鲑鱼降钙素(邦瑞得)与进口鲑鱼降钙素(密盖息)分别联合维D钙咀嚼片(迪巧)治疗原发性骨质疏松症(primary osteoporosis,POP)的疗效。方法 50例POP患者,分成观察组和对照组。对照组迪巧加密盖息治疗。观察组迪巧加邦瑞得治疗。结果观察组显效率为64.00%,有效率为32.00%,无效率为4.00%;对照组显效率为60.00%,有效率为32.00%,无效率为8.00%。组间比较,差异无统计学意义(P>0.05)。治疗前与治疗后,两组患者骨密度比较,差异无统计学意义(P>0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。邦瑞得市场价格要低于密盖息。结论迪巧联合邦瑞得治疗POP患者疗效可靠,安全,而且经济实惠,值得临床应用推广。

Objective To evaluate the efficacy between D-Cal and Miacalcic in the treatment of primary osteoporosis （POP）. Methods We selected 50 cases of POP and divided them into observation group and control group. The control group was treated with D-Cal with Miacalcic,and the observation group was given D-Cal with Bangruide. Results In the observation group,the markedly effective rate was 64.00%,the effective rate was 32.00% and the invalid rate was 4.00%,and they were 60.00%,32.00% and 8.00%,respectively in the control group,with no significant difference between the two groups （P〉0.05）.There was no significant difference in bone density before and after treatment between the two groups （P〉0.05）. There was no significant difference in the adverse reaction rate of the two groups （P〉0.05）.The market price of Bangruide was lower than that of Miacalcic. Conclusion D-Cal combined with Bangruide in the treatment of POP shows reliable and safe efficacy,with lower cost,worthy of clinical application and popularization.